163 related articles for article (PubMed ID: 2457072)
1. In vivo and in vitro studies of microsphere pancreatic supplements.
Littlewood JM; Kelleher J; Walters MP; Johnson AW
J Pediatr Gastroenterol Nutr; 1988; 7 Suppl 1():S22-9. PubMed ID: 2457072
[TBL] [Abstract][Full Text] [Related]
2. Comparison of four pancreatic extracts in cystic fibrosis.
Beverley DW; Kelleher J; MacDonald A; Littlewood JM; Robinson T; Walters MP
Arch Dis Child; 1987 Jun; 62(6):564-8. PubMed ID: 3304172
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of pancreatic enzyme supplementation in children with cystic fibrosis: comparison of two preparations by random crossover study and a retrospective study of the same patients at two different ages.
Ansaldi-Balocco N; Santini B; Sarchi C
J Pediatr Gastroenterol Nutr; 1988; 7 Suppl 1():S40-5. PubMed ID: 3042938
[TBL] [Abstract][Full Text] [Related]
4. In vitro dissolution profiles of enteric-coated microsphere/microtablet pancreatin preparations at different pH values.
Gan KH; Geus WP; Bakker W; Lamers CB; Heijerman HG
Aliment Pharmacol Ther; 1996 Oct; 10(5):771-5. PubMed ID: 8899086
[TBL] [Abstract][Full Text] [Related]
5. A comparison of two pancreatin microsphere preparations in cystic fibrosis.
Elliott RB; Escobar LC; Lees HR; Akroyd RM; Reilly HC
N Z Med J; 1992 Mar; 105(930):107-8. PubMed ID: 1553114
[TBL] [Abstract][Full Text] [Related]
6. Pancrease gastroresistance: in vitro evaluation of pH-determined dissolution.
Lenaerts C; Beraud N; Castaigne JP
J Pediatr Gastroenterol Nutr; 1988; 7 Suppl 1():S18-21. PubMed ID: 3404358
[TBL] [Abstract][Full Text] [Related]
7. Pancreatin preparations used in the treatment of cystic fibrosis--lipase content and in vitro release.
Walters MP; Littlewood JM
Aliment Pharmacol Ther; 1996 Jun; 10(3):433-40. PubMed ID: 8791974
[TBL] [Abstract][Full Text] [Related]
8. In vitro comparative study of three pancreatic enzyme preparations: dissolution profiles, active enzyme release and acid stability.
Aloulou A; Puccinelli D; Sarles J; Laugier R; Leblond Y; Carrière F
Aliment Pharmacol Ther; 2008 Feb; 27(3):283-92. PubMed ID: 17973644
[TBL] [Abstract][Full Text] [Related]
9. Mismatch of duodenal deliveries of dietary fat and pancreatin from enterically coated microspheres.
Meyer JH; Lake R
Pancreas; 1997 Oct; 15(3):226-35. PubMed ID: 9336785
[TBL] [Abstract][Full Text] [Related]
10. Two enteric coated microspheres in cystic fibrosis.
Williams J; MacDonald A; Weller PH; Fields J; Pandov H
Arch Dis Child; 1990 Jun; 65(6):594-7. PubMed ID: 2198848
[TBL] [Abstract][Full Text] [Related]
11. Malabsorption in cystic fibrosis: mechanisms and treatment.
Bouquet J; Sinaasappel M; Neijens HJ
J Pediatr Gastroenterol Nutr; 1988; 7 Suppl 1():S30-5. PubMed ID: 3404359
[TBL] [Abstract][Full Text] [Related]
12. Comparison of two enteric coated microsphere preparations in the treatment of pancreatic exocrine insufficiency caused by cystic fibrosis.
Santini B; Antonelli M; Battistini A; Bertasi S; Collura M; Esposito I; Di Febbraro L; Ferrari R; Ferrero L; Iapichino L; Lucidi V; Manca A; Pisconti CL; Pisi G; Raia V; Romano L; Rosati P; Grazioli I; Melzi G
Dig Liver Dis; 2000; 32(5):406-11. PubMed ID: 11030186
[TBL] [Abstract][Full Text] [Related]
13. Comparison of a high lipase pancreatic enzyme extract with a regular pancreatin preparation in adult cystic fibrosis patients.
Gan KH; Heijerman HG; Geus WP; Bakker W; Lamers CB
Aliment Pharmacol Ther; 1994 Dec; 8(6):603-7. PubMed ID: 7696449
[TBL] [Abstract][Full Text] [Related]
14. Faecal bile acid and dietary residue excretion in cystic fibrosis: age group variations.
Walters MP; Littlewood JM
J Pediatr Gastroenterol Nutr; 1998 Sep; 27(3):296-300. PubMed ID: 9740200
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic potential and clinical efficacy of acid-resistant fungal lipase in the treatment of pancreatic steatorrhoea due to cystic fibrosis.
Zentler-Munro PL; Assoufi BA; Balasubramanian K; Cornell S; Benoliel D; Northfield TC; Hodson ME
Pancreas; 1992; 7(3):311-9. PubMed ID: 1594552
[TBL] [Abstract][Full Text] [Related]
16. Comparison of gastrointestinal pH in cystic fibrosis and healthy subjects.
Youngberg CA; Berardi RR; Howatt WF; Hyneck ML; Amidon GL; Meyer JH; Dressman JB
Dig Dis Sci; 1987 May; 32(5):472-80. PubMed ID: 3646103
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of pancrease: crossover comparative study versus eurobiol in cystic fibrosis.
Chazalette JP; Dain MP; Castaigne JP
J Pediatr Gastroenterol Nutr; 1988; 7 Suppl 1():S46-8. PubMed ID: 3042939
[TBL] [Abstract][Full Text] [Related]
18. In Vitro Comparison of Physical Parameters, Enzyme Activity, Acid Resistance, and pH Dissolution Characteristics of Enteric-Coated Pancreatic Enzyme Preparations: Implications for Clinical Variability and Pharmacy Substitution.
Kuhn RJ; Eyting S; Henniges F; Potthoff A
J Pediatr Pharmacol Ther; 2007 Apr; 12(2):115-28. PubMed ID: 23055848
[TBL] [Abstract][Full Text] [Related]
19. Solubility of oral pancreatic enzyme supplement capsules in biological fluids.
Robb TS; Davidson GP; Cooper DM
Lancet; 1980 Sep; 2(8193):544. PubMed ID: 6105599
[No Abstract] [Full Text] [Related]
20. Comparative evaluation of the therapeutic efficacy of a pH-sensitive enteric coated pancreatic enzyme preparation with conventional pancreatic enzyme therapy in the treatment of exocrine pancreatic insufficiency.
Dutta SK; Rubin J; Harvey J
Gastroenterology; 1983 Mar; 84(3):476-82. PubMed ID: 6549746
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
